Veru Inc.

VERU

US92536C1036

Personal Products

Real-time Estimate Cboe BZX Other stock markets 11:58:15 04/06/2024 pm IST			5-day change	1st Jan Change
0.998 ^USD	-1.19%		-10.72%	+37.64%

22/05	Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	CI
14/05	B. Riley Securities Starts Very With Buy Rating, $5 Price Target	MT

Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022

May 18, 2022 at 06:00 pm IST

Veru Inc. announced the appointment of Joel Batten as Executive Vice President and Head of its U.S. Infectious Disease Franchise effective May 23, 2022. Most recently Mr. Batten has been the Head of the Respiratory Syncytial Virus Franchise at Sobi North America where he was responsible for the Synagis business with gross revenue of approximately $600 million and a team of over 160 employees.

Latest news about Veru Inc.

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	22/05	CI
B. Riley Securities Starts Very With Buy Rating, $5 Price Target	14/05	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	08/05	CI
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	08/05	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	08/05
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	06/05	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04	CI
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	15/04	MT
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02/04	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	28/03	MT
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03	CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03	CI
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	12/03	CI
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	20/02	CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024	08/02
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	06/02	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	08/01	CI
Transcript : Veru Inc. - Special Call	04/01
Veru Prices $33 Million Offering; Shares Fall	15/12	MT
Veru Launching Public Offering of Shares	14/12	MT
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	09/12	CI
North American Morning Briefing : Stock Futures, -2-	04/12	DJ
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	04/23/04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	26/23/26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	11/23/11	CI

Chart Veru Inc.

Duration

Period

More charts

Company Profile

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

More about the company